TransMedics Group (NASDAQ:TMDX) Stock Price Down 2.6% - Should You Sell?

TransMedics Group, Inc. (NASDAQ:TMDX - Get Free Report) shares dropped 2.6% during trading on Tuesday . The stock traded as low as $84.00 and last traded at $84.57. Approximately 112,587 shares were traded during mid-day trading, a decline of 92% from the average daily volume of 1,330,884 shares. The stock had previously closed at $86.84.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. Canaccord Genuity Group reissued a "buy" rating and set a $104.00 target price on shares of TransMedics Group in a report on Tuesday, March 11th. Needham & Company LLC reissued a "hold" rating on shares of TransMedics Group in a report on Wednesday, March 26th. Three investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $122.70.

TransMedics Group Price Performance

The firm's 50-day moving average is $72.48 and its 200-day moving average is $79.89. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42. The company has a market capitalization of $2.98 billion, a PE ratio of 93.87 and a beta of 2.14.

Hedge Funds Weigh In On TransMedics Group

A number of hedge funds and other institutional investors have recently modified their holdings of TMDX. Cornerstone Wealth Management LLC lifted its position in TransMedics Group by 68.5% in the 1st quarter. Cornerstone Wealth Management LLC now owns 6,247 shares of the company's stock worth $420,000 after buying an additional 2,540 shares during the last quarter. Janney Montgomery Scott LLC lifted its holdings in shares of TransMedics Group by 129.9% in the 1st quarter. Janney Montgomery Scott LLC now owns 8,799 shares of the company's stock worth $592,000 after acquiring an additional 4,972 shares during the last quarter. Campbell Newman Asset Management Inc. grew its holdings in shares of TransMedics Group by 1.4% during the 1st quarter. Campbell Newman Asset Management Inc. now owns 11,619 shares of the company's stock valued at $782,000 after purchasing an additional 166 shares during the last quarter. SG Americas Securities LLC raised its position in TransMedics Group by 132.2% in the 1st quarter. SG Americas Securities LLC now owns 14,126 shares of the company's stock worth $950,000 after purchasing an additional 8,043 shares during the period. Finally, GAMMA Investing LLC lifted its stake in TransMedics Group by 551.7% in the first quarter. GAMMA Investing LLC now owns 1,564 shares of the company's stock worth $105,000 after purchasing an additional 1,324 shares during the last quarter. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.